NASHVILLE, Tenn., Nov. 2 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that Chief Executive Officer A.J. Kazimi and Chief Commercial Officer Martin E. Cearnal will present an update on the company at the Lazard Healthcare Conference in New York at 10:25 a.m. Eastern Time on Tuesday, November 17, 2009.
The presentation will be simultaneously webcast and can be accessed by visiting the Investor Relations section on Cumberland Pharmaceuticals' website at www.cumberlandpharma.com. Shortly following the live webcast, a replay will be available and archived for 90 days.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland markets Acetadote® for the treatment of acetaminophen poisoning and Kristalose®, a prescription laxative. The Company also recently launched Caldolor®, the first injectable treatment for pain and fever approved in the United States. Cumberland is dedicated to providing innovative products which improve quality of care for patients. The Company completed its initial public offering of common stock in August 2009.
For more information on Cumberland Pharmaceuticals, please visit www.cumberlandpharma.com.
SOURCE: Cumberland Pharmaceuticals Inc.
SOURCE Cumberland Pharmaceuticals Inc.
|SOURCE Cumberland Pharmaceuticals Inc.|
Copyright©2009 PR Newswire.
All rights reserved